Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Study on Sequential Therapy With Dacomitinib as First-line Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

NCT04768491 is registered in ClinicalTrials.gov with Peking Union Medical College as lead sponsor.

NCT NCT04768491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Study on Sequential Therapy With Dacomitinib as First-line Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Lead sponsor
Peking Union Medical College
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2020
Completion date
October 31, 2024
Enrollment
82 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, nsclc stage iiib, nsclc stage iv, nsclc, recurrent